Rhythm PharmaceuticalsRYTM
RYTM
About: Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
Employees: 226
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
868% more call options, than puts
Call options by funds: $46M | Put options by funds: $4.75M
72% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 18
25% more funds holding in top 10
Funds holding in top 10: 8 [Q2] → 10 (+2) [Q3]
23% more capital invested
Capital invested by funds: $2.88B [Q2] → $3.55B (+$672M) [Q3]
7% more funds holding
Funds holding: 164 [Q2] → 175 (+11) [Q3]
7% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 55
4.06% less ownership
Funds ownership: 114.85% [Q2] → 110.78% (-4.06%) [Q3]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$64
7%
upside
Avg. target
$71
18%
upside
High target
$80
33%
upside
7 analyst ratings
7 positive
100%
0 neutral
0%
0 negative
0%
JMP Securities Jonathan Wolleben 42% 1-year accuracy 32 / 76 met price target | 25%upside $75 | Market Outperform Reiterated | 23 Dec 2024 |
HC Wainwright & Co. Raghuram Selvaraju 42% 1-year accuracy 138 / 329 met price target | 15%upside $69 | Buy Reiterated | 23 Dec 2024 |
Oppenheimer Leland Gershell 44% 1-year accuracy 24 / 55 met price target | 27%upside $76 | Outperform Initiated | 20 Dec 2024 |
Goldman Sachs Corinne Jenkins 33% 1-year accuracy 2 / 6 met price target | 10%upside $66 | Buy Maintained | 5 Dec 2024 |
Canaccord Genuity Whitney Ijem 31% 1-year accuracy 12 / 39 met price target | 33%upside $80 | Buy Maintained | 19 Nov 2024 |
Financial journalist opinion
Based on 3 articles about RYTM published over the past 30 days
Positive
Zacks Investment Research
1 week ago
Wall Street Analysts Think Rhythm Pharmaceuticals (RYTM) Could Surge 26.36%: Read This Before Placing a Bet
The consensus price target hints at a 26.4% upside potential for Rhythm Pharmaceuticals (RYTM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Positive
Zacks Investment Research
1 week ago
Rhythm Pharmaceuticals (RYTM) Soars 5.5%: Is Further Upside Left in the Stock?
Rhythm Pharmaceuticals (RYTM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Neutral
GlobeNewsWire
3 weeks ago
Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones
-- Preliminary unaudited net revenues from global sales of IMCIVREE ® (setmelanotide) of approximately $42 million for the fourth quarter of 2024 and approximately $130 million for the full year of 2024 -- -- On track to report topline data from global Phase 3 trial evaluating setmelanotide in acquired hypothalamic obesity in the first half of 2025 --
Positive
Benzinga
1 month ago
Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential
Oppenheimer initiated coverage on Rhythm Pharmaceuticals Inc. RYTM, a developer of treatment for rare obesity disorders.
Neutral
GlobeNewsWire
1 month ago
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old
BOSTON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for IMCIVREE® (setmelanotide) to include children as young as 2 years old. IMCIVREE is indicated to reduce excess body weight and maintain weight reduction long-term in patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency.
Neutral
GlobeNewsWire
2 months ago
Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old
BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the United Kingdom's Medicines & Healthcare products Regulatory Agency (MHRA) has expanded the marketing authorization for IMCIVREE® (setmelanotide) to include the treatment of obesity and control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS) or genetically confirmed loss-of-function biallelic pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or biallelic leptin receptor (LEPR) deficiency in adult and pediatric patients as young as 2 years old and older.
Neutral
Investors Business Daily
2 months ago
Biotech Stock Attempts To End Losing Streak, Lands Back in Buy Zone
This biotech stock is back in a buy zone after a sharp sell-off. The company makes an obesity drug and develops treatments for rare diseases.
Neutral
GlobeNewsWire
2 months ago
Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide
-- Four Pediatric patients treated in French early-access program achieved meaningful weight reduction at three months on setmelanotide therapy -- -- Rhythm announced plans for a new substudy to evaluate setmelanotide therapy in patients with congenital hypothalamic obesity --
Neutral
GlobeNewsWire
2 months ago
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of results from its Phase 3 VENTURE trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, in children between the ages of 2 and younger than 5 years old with Bardet Biedl syndrome (BBS) or pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency. The data are published in the peer-reviewed journal The Lancet Diabetes & Endocrinology .
Neutral
GlobeNewsWire
2 months ago
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that on November 7, 2024, the Compensation & Management Development Committee of Rhythm's Board of Directors granted inducement restricted stock units, or RSUs, covering an aggregate of 15,750 shares of its common stock to three new employees.
Charts implemented using Lightweight Charts™